Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

18.95 -1.88 (-9.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 326,463
Open 20.59
Bid (Size) 19.21 (12)
Ask (Size) 20.77 (5)
Prev. Close 20.83
Today's Range 18.71 - 20.94
52wk Range 14.30 - 45.00
Shares Outstanding 26,562,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire

Performance

YTD
+11.01%
+11.01%
1 Month
+0.64%
+0.64%
3 Month
-15.67%
-15.67%
6 Month
-15.70%
-15.70%
1 Year
-41.96%
-41.96%

More News

Read More
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Unveiling 3 Analyst Insights On Arcturus Therapeutics
Via Benzinga
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
From Meiji Seika Pharma Co., Ltd. and ARCALIS, Inc.
Via Business Wire
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Via Benzinga
Exposures COVID-19
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
Via Benzinga
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
Via Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
Via Benzinga
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.